Table 3.
CYP2C19 isoenzyme and the influence of its mutations on the metabolism of voriconazole and the drug serum levels
| Allele | Enzymatic activity | Percentage in population | CYP2C19 genotype | Type of metabolism | Changes of serum levels after standard dose application | ||
|---|---|---|---|---|---|---|---|
| Caucasian | Afro-American | Asiatic | |||||
| *2 | loss | 12 | 15 | 29–35 | *2/*2 | PM | ↑ |
| *1/*2 | IM | ||||||
| *3 | ↓ | < 1 | < 1 | 2–9 | *1/*3 | IM | |
| *2/*3 | PM | ↑ | |||||
| *3/*3 | PM | ||||||
| *4 | ↓ | < 1 | < 1 | < 1 | *1/*4 | IM | ↑ |
| *5 | ↓ | < 1 | < 1 | < 1 | *1/*5 | IM | ↑ |
| *6 | ↓ | < 1 | < 1 | < 1 | *1/*6 | IM | ↑ |
| *7 | ↓ | < 1 | < 1 | < 1 | *1/*7 | IM | ↑ |
| *8 | ↓ | < 1 | < 1 | < 1 | *1/*8 | IM | ↑ |
| *17 | ↑ | 21 | 16 | 3 | *1/*17 | EM | ↓ |
| *17/*17 | UM | ||||||
PM – poor metabolism; IM – intermediate metabolism; EM – extensive metabolism; UM – ultra rapid metabolism